Clinical Trial Update: Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of Lanreotide Autogel in combination with Temozolomide for thoracic neuroendocrine tumors; trial completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Lanreotide Autogel (lanreotide)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Ipsen | Conditions: Neuroendocrine Tumours | Phase 2 | Status: COMPLETED | Results posted: 2020-10-01